The updated Alphabet Strategy: Facilitating the implementation of NICE guidelines

Diabetes and Primary Care

Volumn 11, Issue 3, 2009, Pages 148-158

  Alsafadi, Hala ^a   Morrissey, John ^a   Patel, Vinod ^b  

^a Diabetes and Endocrinology ^*  (United States)

^b GEORGE ELIOT HOSPITAL   (United Kingdom)

Author keywords

Alphabet Strategy; NICE guidelines; Type 2 diabetes

Indexed keywords

EID: 68149148976     PISSN: 14668955     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-59
2. ADVANCE Collaborative Group, Patel A, MacMahon S et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-72
3. Booth GL, Kapral MK, Fung K et al (2006) Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 368:29-36
4. Davies MJ, Heller S, Skinner TC et al (2008) Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 336:491-5
5. Department of Health (2008) High Quality Care For All: NHS Next Stage Review. Final Report. DH, London
6. Estacio RO, Jeffers BW, Gifford N et al (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23 (Suppl 2): B54-64
7. Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 356: 580-91
8. Griebenow R (2005) [The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin]. Internist (Berl) 46: 350-2
9. Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-9
10. Holman RR, Paul SK, Bethel MA et al (2008a) Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359: 1565-76
11. Holman RR, Paul SK, Bethel MA et al (2008b) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-89
12. Holzer SE, Camerota A, Martens L (1998) Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther 20:169-81
13. Huxley RF, Barzi F, Woodward M (2006) Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332:73-8
14. International Diabetes Federation (2006) Diabetes Atlas. 3rd edn. International Diabetes Federation, Brussels
15. Jacobs MJ, Kleisli T, Pio JR et al (2005) Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 70:263-9
16. Keech A, Simes RJ, Barter P et al (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849-61
17. Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403
18. Laing SP, Swerdlow AJ, Slater SD (2003) Mortality from heart disease in a cohort of 23, 000 patients with insulin-treated diabetes. Diabetologia 46: 760-5
19. Lindstrom J, Louheranta A, Mannelin M et al (2003) The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26: 3230-6
20. National Collaborating Centre for Chronic Conditions (2008) Type 2 Diabetes: The Management of Type 2 Diabetes (Update). NICE, London. Available at: http://tiny.cc/rBjZa (accessed 01.06.09)
21. NICE (2004) Type 2 diabetes: Prevention and Management of Foot Problems: CG10. NICE, London. Available at: http://tiny.cc/haogl (accessed 27.05.09)
22. NICE (2009) Type 2 Diabetes: Newer Agents for Blood Glucose Control in Type 2 Diabetes. NICE, London. Available at: http://tiny.cc/HBsbC (accessed 01.06.09)
23. Patel V, Morrissey J (2002) The Alphabet Strategy: The ABC of reducing diabetes complications. Br J Diabetes Vasc Dis 2: 58-59
24. Patel A, ADVANCE Collaborative Group, MacMahon S et al (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370: 829-40
25. Perusicova J (2001) [Prevalence of dyslipidaemia, hypertension and vascular complications in newly diagnosed diabetics (prospective study: part 2)]. Vnitr Lek 47: 146-50
26. Poulter NR, Wedel H, Dahl B et al (2005) Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 366: 907-13
27. Pyorala K, Pedersen TR, Kjekshus J et al (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-20
28. Ridker PM, Morrow DA, Rose LM et al (2005) Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/1: an analysis of the PROVE-ITTIMI-22 trial JAm Coll Cardiol 45: 1644-8
29. Stratton IM, Adler Al, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-12
30. UK Prospective Diabetes Study Group (1998a) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703-13
31. UK Prospective Diabetes Study Group (1998b) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-53
32. UK Prospective Diabetes Study Group (1998c) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-65
33. Wild S, Roglic G, Green A et al (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-53
34. Williams R, Van Gaal L, Lucioni C et al (2002) Assessing the impact of complications on the costs of type II diabetes. Diabetologia 45: S13-17
35. Williams B (2003) Epidemiology and Pathogenesis of hypertension in diabetes. In: Williams B (ed). Hypertension in Diabetes. Martin Dunitz, London
36. Younis N, Broadbent DM, Harding SP, Vora JP (2003) Incidence of sight-threatening retinopathy in type 1 diabetes in a systematic screening programme. Diabet Med 20:758-65